(Q36870401)

English

A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation

scientific article published on 26 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 August 2017

A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation (English)

1 reference

Europe PubMed Central

16 August 2017

chemoradiotherapy

0 references

head and neck cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

head and neck carcinoma

1 reference

based on heuristic

inferred from title

Everett E Vokes

12

object named as

E E Vokes

1 reference

Europe PubMed Central

16 August 2017

3

object named as

D Haraf

1 reference

Europe PubMed Central

16 August 2017

Tanguy Y Seiwert

1

object named as

T Y Seiwert

1 reference

Europe PubMed Central

16 August 2017

Kerstin Stenson

5

object named as

K Stenson

1 reference

Europe PubMed Central

16 August 2017

author name string

T Darga

2

1 reference

Europe PubMed Central

16 August 2017

E A Blair

4

1 reference

Europe PubMed Central

16 August 2017

E E W Cohen

6

1 reference

Europe PubMed Central

16 August 2017

J K Salama

7

1 reference

Europe PubMed Central

16 August 2017

V Villaflor

8

1 reference

Europe PubMed Central

16 August 2017

M E Witt

9

1 reference

Europe PubMed Central

16 August 2017

M W Lingen

10

1 reference

Europe PubMed Central

16 August 2017

R R Weichselbaum

11

1 reference

Europe PubMed Central

16 August 2017

publication date

26 October 2012

1 reference

Europe PubMed Central

16 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

16 August 2017

24

1 reference

Europe PubMed Central

16 August 2017

3

1 reference

Europe PubMed Central

16 August 2017

769-776

1 reference

Europe PubMed Central

16 August 2017

Tumor necrosis factor-related genes and colon and rectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

Adenovirus-associated virus vector-mediated gene transfer in hemophilia B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

Efficacy of gene therapy for X-linked severe combined immunodeficiency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

Ionizing radiation: a genetic switch for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

Radiation Therapy—Activation of Gene Transcription and the Development of Genetic Radiotherapy: Therapeutic Strategies in Oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

29 September 2017

A tale of two SCIDs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

27 June 2018

TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

27 June 2018

Design and analysis of phase I clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

27 June 2018

The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

27 June 2018

The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

27 June 2018

Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

4 September 2018

Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

4 September 2018

Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

4 September 2018

Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

4 September 2018

Gene therapy for immunodeficiency due to adenosine deaminase deficiency.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

4 September 2018

Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

4 September 2018

Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

4 September 2018

Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

4 September 2018

Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

4 September 2018

Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

4 September 2018

Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

4 September 2018

Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

4 September 2018

Gene therapy death--"everyone has to share in the guilt".

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

4 September 2018

Spatial and temporal control of gene therapy using ionizing radiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3662388

4 September 2018

Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23104721

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose reirradiation of head and neck cancer with curative intent

1 reference

https://pubmed.ncbi.nlm.nih.gov/23104721

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911

1 reference

https://pubmed.ncbi.nlm.nih.gov/23104721

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/23104721

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23104721

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23104721

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23104721

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/23104721

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDS523

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

1 reference

Europe PubMed Central

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36870401&oldid=2087939628"